Genovis AB operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genovis AB with three other
companies in this sector in Sweden:
Xbrane Biopharma Ab
sales of 20.77 million Swedish Kronor [US$2.47 million]
Sprint Bioscience AB
(23.97 million Swedish Kronor [US$2.85 million]
(20.69 million Swedish Kronor [US$2.46 million]
During the year ended December of 2017, sales at
Genovis AB were SEK 22.89 million (US$2.72 million).
decrease of 3.2%
versus 2016, when the company's sales were SEK 23.64 million.